CJC-1295 vs Ipamorelin
The two halves of the most popular research-peptide "GH stack" compared — a GHRH analog and a ghrelin-receptor agonist, both of which raise growth hormone but neither of which has proven clinical benefit.
These are the two halves of the most common growth-hormone "stack," and they work by different but complementary mechanisms — CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor. Both raise growth hormone, which is a biomarker effect, and neither has any controlled human trial showing the fat-loss, muscle, or anti-aging outcomes they are marketed for. Both are unapproved research chemicals, both are prohibited in sport, and the stack itself has never been studied for safety or efficacy. The honest comparison is not "which is better" but "both are unproven in humans."
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Mechanism | GHRH analog — acts on the GHRH receptor on pituitary somatotrophs | Ghrelin / GH-secretagogue receptor agonist (GHS-R1a) — a different pathway |
| Regulatory status | Research chemical — never FDA-approved for any use | Research chemical — never FDA-approved; development halted after early trials |
| Best evidence | Grade C — raises GH and IGF-1 in one small human study | Grade C — raises GH selectively, from limited human pharmacology data |
| Human trial evidence | A single phase-1/2 pharmacokinetic study; no clinical-outcome trials | Small pharmacology studies; a phase-2 post-operative-ileus trial failed (Grade E) and development stopped |
| Fat loss / muscle | Grade U — no human outcome trials | Grade U — no human outcome trials |
| Half-life / dosing | With DAC ~6–8 days; without DAC (Modified GRF 1-29) ~30 minutes | Roughly 2 hours in humans |
| Common side effects / safety | Injection-site reactions, flushing, headache; long-term safety unknown | Injection-site reactions, headache, flushing, transient hunger; long-term safety unknown |
| WADA status | Prohibited at all times (S2) | Prohibited at all times (S2) |
| Product quality / the 'stack' | Unregulated supply; commonly stacked with ipamorelin, a combination never studied | Unregulated supply; commonly stacked with CJC-1295, a combination never studied |
How to read this comparison
CJC-1295 and ipamorelin are almost always discussed together, because they are the classic two-part “GH stack” sold on the research-chemical market. The rationale offered is that they hit growth-hormone release through two different doors — CJC-1295 as a GHRH analog on the GHRH receptor, ipamorelin as a ghrelin-mimetic on the GHS-R1a receptor — so combining them is meant to be synergistic.
That mechanistic story is real as far as it goes. What it does not establish is any clinical result. For both compounds, the human evidence stops at the same place: a biomarker effect — they raise growth hormone (Grade C for each, from thin human data). The leap from there to fat loss, muscle gain, recovery, or anti-aging is exactly where the evidence runs out. Every one of those outcomes is Grade U — no randomized human trial has tested them for either compound.
Ipamorelin’s record actually carries one instructive negative: its most rigorous human indication, post-operative ileus, was tested in a phase-2 program that did not succeed, and development was discontinued (Grade E). That is worth weighing against the marketing — the one time ipamorelin was put to a real clinical test, it failed it. CJC-1295’s human evidence is even thinner: a single pharmacokinetic study, with the added complication that “with DAC” and “without DAC” (Modified GRF 1-29) are different molecules with wildly different half-lives sold under one name.
The most important point about the stack is the one the marketing never mentions: the combination has never been studied. Stacking two compounds whose individual outcome grades are U does not produce a proven result — it produces two unknowns taken together. Both are unregulated research chemicals of uncertain purity and dose, both are prohibited in sport under WADA’s S2 category, and neither is a legal therapeutic.
The honest comparison is not which of these is better. It is that both raise a hormone and neither has been shown to do anything worthwhile — or to be safe long-term — in humans. This page summarizes the research record; it is not medical advice or an endorsement of use.
A note on "dose"
Any doses shown here are the amounts studied in trialsor the approved label schedule — not a recommendation, and not the same thing as a dose someone reports using online. See how we separate dose language.
References